2024
608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
Park W, Kasi A, Spira A, Berlin J, Wang J, Herzberg B, Kuboki Y, Kitano S, Pelster M, Goldman J, Morgensztern D, Kondo S, Jänne P, Fujii H, Lee H, Gill S, Saci A, Lorusso P, Tolcher A. 608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Annals Of Oncology 2024, 35: s486-s487. DOI: 10.1016/j.annonc.2024.08.675.Peer-Reviewed Original Research
2023
1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Olszanski A, Luke J, LoRusso P, Falchook G, Bedard P, Sanborn R, Patel S, Orr D, Gibbs J, Li C, Huang Y, Gregory R, Perera S, Xu R, Joshi A, Lee M, Raizer J, Gao X. 1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE). Annals Of Oncology 2023, 34: s625-s626. DOI: 10.1016/j.annonc.2023.09.2168.Peer-Reviewed Original Research
2008
Patupilone combined with carboplatin in patients (pts) with advanced solid tumors: preliminary safety and activity results
Fracasso P, Ravaud A, Baggstrom M, LoRusso P, Jones D, Sguotti C, Urban P, Gao B, Medioni J. Patupilone combined with carboplatin in patients (pts) with advanced solid tumors: preliminary safety and activity results. Journal Of Clinical Oncology 2008, 26: 13544-13544. DOI: 10.1200/jco.2008.26.15_suppl.13544.Peer-Reviewed Original Research